Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.59 |
| ▸ | MAOA | P21397 | 6/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | CALML3 | P27482 | 1/20 | 0.47 |
| ▸ | SDHA | P31040 | 1/20 | 0.47 |
| ▸ | F10 | P00742 | 12/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5378887 | 0.96 | MAOB (0.63) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL5370541 | 0.93 | MAOB (0.59) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL14370624 | 0.93 | MAOB (0.59) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL5378892 | 0.89 | MAOB (0.63) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL14370620 | 0.89 | MAOB (0.63) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL5370547 | 0.89 | MAOB (0.61) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL14370625 | 0.89 | MAOB (0.61) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL4879564 | 0.87 | MAOA (0.62) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL14370628 | 0.87 | MAOB (0.58) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL5382708 | 0.87 | MAOB (0.58) | MAOBMAOALMNAPTGS1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279494-B2 | Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues | PFIZER INC. (US) | 2007-10-09 | — | — | US | claimed |
| US-20050192325-A1 | Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues | RENSLO ADAM (US) | 2005-09-01 | — | — | US | claimed |
| US-7279494-B2 | Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues | PFIZER INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-20050192325-A1 | Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues | RENSLO ADAM (US) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192325-A1 | Antimicrobial [3.1.0] bicyclohexylphenyl-oxazolidinone derivatives and analogues | OXA1L, CYP51A1, CYP2C19 | MAOB 1797/4885MAOA 1957/4885LMNA 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.